ARTICLE | Company News
Memory, Amgen PDE-10 deal
October 18, 2005 1:09 AM UTC
MEMY granted AMGN an exclusive worldwide license to develop MEMY's preclinical phosphodiesterase-10 (PDE-10) inhibitors to treat neurological and psychiatric disorders. MEMY will receive $5 million up...